Drug Combination Details
| General Information of the Combination (ID: C90835) | |||||
|---|---|---|---|---|---|
| Name | Isoliquiritigenin NP Info | + | Docosahexaenoic acid Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| Up-regulation | ROS generation | |||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Isoliquiritigenin in combination with docosahexaenoic acid has synergistic anticancer effect on human colorectal cancer cells through ROS-mediated regulation of the JNK and cytochrome c release. | |||||
